Systemic immunotherapy for the treatment of brain metastases

Frontiers in Oncology

Volumn 6, Issue MAR, 2016, Pages

  Cohen, Justine V ^a   Kluger, Harriet M ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Brain metastases; Immunotherapy; Melanoma

Indexed keywords

BEVACIZUMAB; FOTEMUSTINE; IMMUNOMODULATING AGENT; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB;

BRAIN METASTASIS; CANCER IMMUNOTHERAPY; DISEASE CONTROL; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; LUNG CANCER; METASTATIC MELANOMA; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; TREATMENT RESPONSE; UPREGULATION;

EID: 84964413448     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00049     Document Type: Note

References (59)

1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 372(21):2018-28. doi:10.1056/NEJMoa1501824
2. Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts (2015) 33(15_suppl):LBA109
3. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol (2015) 16(4):375-84. doi:10.1016/S1470-2045(15)70076-8
4. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med (2015) 373(19):1803-13. doi:10.1056/NEJMoa1510665
5. McDermott D, Haanen J, Chen TT, Lorigan P, O'Day S, Investigators MDX. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol (2013) 24(10):2694-8. doi:10.1093/annonc/mdt291
6. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366(26):2455-65. doi:10.1056/NEJMoa1200694
7. Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A, Li X, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. ASCO Meeting Abstracts (2014) 32(15_suppl):8021
8. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 515(7528):558-62. doi:10.1038/nature13904
9. Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). ASCO Meeting Abstracts (2013) 31(15_suppl):9010
10. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 515(7528):563-7. doi:10.1038/nature14011
11. Tabernero J, Powderly JD, Hamid O, Gordon MS, Fisher GA, Braiteh FS, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors. ASCO Meeting Abstracts (2013) 31(15_suppl):3622
12. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 102(8):1213-8. doi:10.1038/sj.bjc.6605622
13. Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg (2007) 54:241-7
14. Redmond AJ, Diluna ML, Hebert R, Moliterno JA, Desai R, Knisely JP, et al. Gamma knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. J Neurosurg (2008) 109(Suppl):99-105. doi:10.3171/JNS/2008/109/12/S16
15. Brown PD, Asher AL, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. NCCTG N0574 (alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. ASCO Meeting Abstracts (2015) 33(15_suppl):LBA4
16. Di Giacomo AM, Margolin K. Immune checkpoint blockade in patients with melanoma metastatic to the brain. Semin Oncol (2015) 42(3):459-65. doi:10.1053/j.seminoncol.2015.02.006
17. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol (2000) 18(11):2349-51
18. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest (2010) 120(5):1368-79. doi:10.1172/JCI41911
19. Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS (2011) 8(1):4. doi:10.1186/2045-8118-8-4
20. Flanigan JC, Jilaveanu LB, Faries M, Sznol M, Ariyan S, Yu JB, et al. Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer (2011) 35(4):200-10. doi:10.1016/j.currproblcancer.2011.07.003
21. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 22(11):2101-7. doi:10.1200/JCO.2004.11.044
22. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 22(6):1118-25. doi:10.1200/JCO.2004.04.165
23. Green RM, Stewart DJ, Hugenholtz H, Richard MT, Thibault M, Montpetit V. Human central nervous system and plasma pharmacology of mitoxantrone. J Neurooncol (1988) 6(1):75-83. doi:10.1007/BF00163544
24. Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res (1982) 42(6):2474-9
25. Stewart DJ, Lu K, Benjamin RS, Leavens ME, Luna M, Yap HY, et al. Concentration of vinblastine in human intracerebral tumor and other tissues. J Neurooncol (1983) 1(2):139-44
26. Stewart DJ, Richard MT, Hugenholtz H, Dennery JM, Belanger R, Gerin-Lajoie J, et al. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. J Neurooncol (1984) 2(2):133-9
27. Bai H, Han B. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients. Am J Clin Oncol (2013) 36(2):110-5. doi:10.1097/COC.0b013e3182438c91
28. Hata A, Katakami N. Afatinib for erlotinib refractory brain metastases in a patient with EGFR-mutant non-small-cell lung cancer: can high-affinity TKI substitute for high-dose TKI? J Thorac Oncol (2015) 10(7):e65-6. doi:10.1097/JTO.0000000000000479
29. Saleem A, Searle GE, Kenny LM, Huiban M, Kozlowski K, Waldman AD, et al. Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. EJNMMI Res (2015) 5:30. doi:10.1186/s13550-015-0103-5
30. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 13(7):2158-67. doi:10.1158/1078-0432.CCR-06-2070
31. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 86(2):343-9. doi:10.1016/j.ijrobp.2012.12.025
32. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res (2016) 4(2):124-35. doi:10.1158/2326-6066.CIR-15-0151
33. Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother (2002) 25(1):82-7. doi:10.1097/00002371-200201000-00009
34. Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res (2011) 21(6):530-4. doi:10.1097/CMR.0b013e32834d3d88
35. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 15(17):5591-8. doi:10.1158/1078-0432.CCR-09-1024
36. Margolin K, ErnstoffMS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 13(5):459-65. doi:10.1016/S1470-2045(12)70090-6
37. Heller KN, Pavlick AC, Hodi FS, Thompson JA, Margolin KA, Lawrence DP, et al. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. ASCO Meeting Abstracts (2011) 29(15_suppl):8581
38. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 13(9):879-86. doi:10.1016/S1470-2045(12)70324-8
39. Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, RidolfiR, Santinami M, et al. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study. Ann Oncol (2015) 26(4):798-803. doi:10.1093/annonc/mdu577
40. Goldberg SB, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Tsiouris AJ, et al. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. ASCO Meeting Abstracts (2015) 33(15_suppl):8035
41. Kluger HM, Goldberg SB, Sznol M, Tsiouris J, Vortmeyer A, Jilaveanu L, et al. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. ASCO Meeting Abstracts (2015) 33(15_suppl):9009
42. Yushak ML, Chiang VL, Kluger HM. Clinical trials in melanoma patients with brain metastases. Pigment Cell Melanoma Res (2015) 28(6):741-3. doi:10.1111/pcmr.12401
43. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711-23. doi:10.1056/NEJMoa1003466
44. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 117(2):227-33. doi:10.3171/2012.5.JNS111929
45. Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, et al. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol (2015) 17(10):1312-21. doi:10.1093/neuonc/nov093
46. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res (2013) 23(3):191-5. doi:10.1097/CMR.0b013e32835f3d90
47. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med (2013) 2(6):899-906. doi:10.1002/cam4.140
48. Frey B, Rubner Y, Kulzer L, Werthmoller N, Weiss EM, Fietkau R, et al. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother (2014) 63(1):29-36. doi:10.1007/s00262-013-1474-y
49. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 114(3):589-95. doi:10.1182/blood-2009-02-206870
50. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 520(7547):373-7. doi:10.1038/nature14292
51. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 366(10):925-31. doi:10.1056/NEJMoa1112824
52. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys (2015) 92(2):368-75. doi:10.1016/j.ijrobp.2015.01.004
53. Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg (2015):1-7. doi:10.3171/2015.6.JNS142763
54. Torres-Reveron J, Tomasiewicz HC, Shetty A, Amankulor NM, Chiang VL. Stereotactic laser induced thermotherapy (LITT): a novel treatment for brain lesions regrowing after radiosurgery. J Neurooncol (2013) 113(3):495-503. doi:10.1007/s11060-013-1142-2
55. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol (2009) 27(31):5255-61. doi:10.1200/JCO.2009.22.0616
56. De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol (2010) 100(3):443-7. doi:10.1007/s11060-010-0200-2
57. Zustovich F, Ferro A, Farina P. Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series. Clin Genitourin Cancer (2014) 12(3):e107-10. doi:10.1016/j.clgc.2013.12.005
58. Zustovich F, Ferro A, Lombardi G, Farina P, Zagonel V. Bevacizumab-based therapy for patients with brain metastases from non-small-cell lung cancer: preliminary results. Chemotherapy (2014) 60(5-6):294-9. doi:10.1159/000376605
59. Zustovich F, Ferro A, Lombardi G, Zagonel V, Fiduccia P, Farina P. Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series. Anticancer Res (2013) 33(9):4061-5